Seeking Alpha

Amarin (AMRN) has been issued a patent by the USPTO covering the pharmaceutical composition of...

Amarin (AMRN) has been issued a patent by the USPTO covering the pharmaceutical composition of the company's Vascepa capsules. Vascepa has already been approved by the FDA for the treatment of high levels of triglycerides, and the company plans to list the patent in the FDA's Orange Book.
Comments (3)
  • waiting for the NCE. Give it to them!!!
    30 Oct 2012, 10:16 PM Reply Like
  • the NCE is on the way for amarin.and the share going to bee 14.5 soon after thay get the NCE.. AMARIN is a very smart company.with a very good management.MR JOSEPH S ZAKRZEWSKI. already sales lovaza
    to GSK wich is a similar drug.but VASEPA is much better is going to do that again if you are investor you should not bee listening for all of the speculative around the company by speculative analyst you can bee sure that all thay want is to buy your shares in good price.dont let them do this to you.bee strong and hapy'''''
    31 Oct 2012, 12:36 PM Reply Like
  • What is the significance of the patent by the USPTO.and who is theUSPTO?
    31 Oct 2012, 01:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)